Novavax share price logo

Novavax

NASDAQ: NVAX

Mid Cap

$11.26

-1.56

(-12.17%)

as on

Novavax Stock Performance

as on October 17, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $11.11
    $12.83
    downward going graph

    1.33%

    Downside

    13.94%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.20
    $13.39
    downward going graph

    44.94%

    Downside

    18.87%

    Upside

    downward going graph

Novavax share price movements today

Previous Close
$12.82
Open
$12.61
Volume
9.2M
Market Cap
$2.1B
Day's Low - High
$11.11 - $12.83
52 Week Low - High
$6.20 - $13.39

Novavax Historical Returns

1 Month Return
+ 12.6 %
3 Month Return
+ 37.15 %
1 Year Return
+ 39.01 %
3 Year Return
+ 74.57 %
5 Year Return
-93.05 %

Novavax Stock Fundamentals & Key Indicators

Check Novavax market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-1.52

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.38%

PE Ratio (TTM)

-8.43

Industry PE ratio

-11.21

PEG Ratio

0.10

EBITDA

-205.6M

Revenue (TTM)

413.8M

Profit Margin

77.85%

Return On Equity TTM

159.85%

Novavax vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Novavax with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Neutral$2.1B-93.05%-8.4377.85%0.00%
Neutral$94.4B-32.76%-29.64-12.57%0.00%
StrongBuy$128.9B174.93%29.3786.04%0.00%
Buy$80.1B42.93%19.0184.86%0.46%

Stock Returns calculator for Novavax Stock including INR - Dollar returns

The Novavax stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Novavax investment value today

Current value as on today

₹1,50,003

Returns

₹50,003

(+50%)

Returns from Novavax Stock

₹39,012 (+39.01%)

Dollar Impact

₹10,990 (+10.99%)

Analyst Recommendation on Novavax Stock

Based on 2 analysts

HOLD

50.00%

Buy

0.00%

Hold

50.00%

Sell

Based on 2 analysts, 50% of analysts recommend a 'HOLD' rating for Novavax. Average target price of $14.11

Novavax Share Price Target

Get share price movements and forecasts by analysts on Novavax.

What analysts predicted

20.2%UPSIDE

Target Price

$14.11

Current Price

$11.26

Analyzed by

2 Analysts

High

$18

Target

$14.11

Low

$8

Novavax target price $14.11, a slight upside of 20.2% compared to current price of $11.26. According to 2 analysts rating.

Indian Investors' Interest in Novavax Stock

Search interest for Novavax Stock has increased by 25% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:25% versus previous 30 day period

Novavax Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
93
415
84
88
666
239
70
147
139
56
Gross Profit
45
369
23
51
652
225
48
121
108
42
Operating Income
-138
160
-134
-131
515
105
-178
21
-15
-54
EBITDA
-129
179
-105
-53
533
120
-190
28
0
-42
Interest Expense
4
4
4
7
5
5
5
5
-4
5
Depreciation
12
11
12
12
8
7
6
5
3
3
Income Before Tax
-145
164
-122
-73
519
107
-203
17
-8
-51
Income Tax Expense
2
2
-1
7
1
0
0
0
0
1
Net Income
-147
162
-121
-81
518
106
-202
17
-9
-53
Net Profit Margin
48.00%
88.87%
28.27%
58.48%
97.88%
94.05%
69.49%
82.87%
78.00%
74.87%

Novavax Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
31
34
18
22
197
1,598
556
682
1,123
Gross Profit
31
34
-95
22
197
696
212
479
1,052
Operating Income
-171
-173
-120
-416
-1,686
-644
-566
-248
563
EBITDA
-159
-162
-113
-398
-1,680
-604
-487
-108
492
Interest Expense
14
12
13
15
21
19
14
20
22
Depreciation
9
8
5
4
12
29
41
48
27
Income Before Tax
-183
-184
-132
-418
-1,714
-653
-543
-176
442
Income Tax Expense
-
1
-
-
29
4
2
10
1
Net Income
-183
-184
-130
-418
-1,743
-657
-545
-187
440
Net Profit Margin
100.00%
100.00%
-510.02%
100.00%
100.00%
43.55%
38.21%
70.28%
93.67%

Novavax Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-147
162
-121
-81
518
106
-202
17
-9
-53
Operating Cash Flow
-83
314
-144
-173
-185
-127
107
-39
-32
-75
Investing Cash Flow
-7
-372
31
144
-73
111
-136
20
-28
34
Financing Cash Flow
5
258
0
-3
-7
-1
42
-6
37
9
Change in Cash
-87
199
-106
-43
-266
-9
14
-27
-23
-31

Novavax Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-183
-184
-132
-418
-1,743
-657
-545
-187
440
Operating Cash Flow
-138
-184
-136
-42
322
-415
-713
-87
-244
Investing Cash Flow
35
28
38
-377
100
-92
-58
-204
-78
Financing Cash Flow
64
102
98
984
461
324
4
260
27
Change in Cash
-38
-53
0
566
879
-179
-765
-38
-289

Global Institutional Holdings in Novavax

Check out the Institutions with significant holdings in Novavax.

Funds
Holdings
Vanguard
8.80%
VANGUARD INDEX FUNDS
7.76%
iShares
5.08%
SPDR
3.46%
Philippe Laffont
2.33%

Novavax News & Key Events

  • img

    Today's Timeline - 10 September

    Thu, 11:32 PM

    -

    Novavax anticipates $200 million in payments from Sanofi, extending cash runway into the 2030s amid vaccine rollout.

Insights on Novavax

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, NVAX stock has moved up by 12.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 738.2% return, outperforming this stock by 699.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 152.5% return, outperforming this stock by 77.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 17.52M → -53.38M (in $), with an average decrease of 308.3% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 147.13M → 56.69M (in $), with an average decrease of 32.3% per quarter

About Novavax

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
OrganisationNovavax
Headquarters21 Firstfield Road, Gaithersburg, MD, 20878, US
IndustryBiotechnology
CEOJohn Charles Jacobs

Key Management of Novavax

Name

Title

Mr. John Charles Jacobs M.B.A.

President, CEO & Director

Mr. Mark J. Casey Esq., J.D.

Executive VP, Chief Legal Officer & Corporate Secretary

Ms. Elaine O'Hara

Executive VP & Chief Strategy Officer

Mr. Richard P. Crowley

Executive VP & COO

Mr. Troy Morgan Esq., J.D.

Senior VP, Deputy General Counsel & Chief Compliance Officer

Ms. Erika S. Trahan

Associate Director of Investor & Public Relations

Mr. Ian J. Watkins

Executive VP & Chief Human Resources Officer

Ms. Silvia Taylor M.B.A.

Executive VP, Chief Corporate Affairs Officer & Head of Novavax Sweden

Mr. James Patrick Kelly C.F.A.

Executive VP, CFO & Treasurer

Ms. Naina Zaman

Director of Investor Relations

FAQs

What is Novavax share price today?

Novavax share price today is $11.26 as on at the close of the market. Novavax share today touched a day high of $12.83 and a low of $11.11.

What is the 52 week high and 52 week low for Novavax share?

Novavax share touched a 52 week high of $13.39 on and a 52 week low of $6.20 on . Novavax stock price today i.e. is closed at $11.26,which is 15.88% down from its 52 week high and 81.61% up from its 52 week low.

What is Novavax's market capitalisation today?

Novavax market capitalisation is $0.00T as on .

How to invest in Novavax Stock (NVAX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Novavax on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Novavax Stock (NVAX) from India?

Indian investors can start investing in Novavax (NVAX) shares with as little as ₹94.95999908447266 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Novavax stock (as per the Rupee-Dollar exchange rate as on ). Based on Novavax share’s latest price of $11.26 as on October 17, 2026 at 8:46 am IST, you will get 0.8881 shares of Novavax. Learn more about fractional shares .

What are the returns that Novavax has given to Indian investors in the last 5 years?

Novavax stock has given -93.05% share price returns and 26.52% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?